Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results...

Related Keywords

Russia ,Italy ,Ukraine ,United States ,Israel ,American ,Russian ,Pnina Fishman ,Motti Farbstein ,European Medicines Agency ,American Society Of Clinical Oncology ,Telethon Institute Of Genetics ,Drug Administration ,University Of Naples Federico ,Fite Biopharma Ltd ,Development For Treatment Of Lowe Syndrome ,Data Monitoring Committee ,Can Fite Biopharma ,Liver Cancer Study ,Independent Data Monitoring Committee ,Abstract Award ,Breakthrough Abstract Award ,American Society ,Clinical Oncology ,Conquer Cancer Foundationfor ,Cancer Study ,Pancreatic Carcinoma ,Pivotal Phase ,Can Fite Received Green Light ,Lowe Syndrome ,Rare Genetic Disease ,Naples Federico ,Telethon Institute ,Fondazione Telethon ,Executive Chairman ,Fite Biopharma ,Orphan Drug Designation ,Fast Track Designation ,Annual Report ,Markets ,